About
Marker Therapeutics develops multi-antigen recognizing T cell therapies for treating blood cancers and solid tumors, with clinical-stage programs including the Phase 1 candidate MT-601 targeting lymphoma patients who relapsed or are ineligible for anti-CD19 CAR-T therapy.
Explore Marker Therapeutics Inc's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.